XTEND, an AI-powered autonomous robotics firm, won $9 million in defense orders to enhance multi-drone operations for a Middle East customer. The company also secured new U.S. and Israeli patents protecting critical UAV navigation and control technologies, reinforcing its competitive edge. These developments support XTEND's growth and upcoming NYSE listing, highlighting its role in advancing autonomous defense systems globally. The firm has also achieved multiple contracts and regulatory milestones across various regions since merging with JFB Construction Holdings in early 2026.
A KAYAK survey of 2,000 Brazilian travelers revealed Cristiano Ronaldo as the most desired football companion for trips, chosen by 60% of respondents. Vinícius Júnior and Endrick followed with 19% and 9%, respectively. The Northeast region of Brazil,...
A KAYAK survey of 2,000 Brazilian travelers found Cristiano Ronaldo is the most desired football player to travel with, chosen by 60% of respondents. Vinícius Júnior and Endrick followed with 19% and 9% respectively. Most Brazilians (59%) would take ...
The 16th annual PODD (Partnership Opportunities in Drug Delivery) conference will take place on October 29-30, 2026, in Boston, gathering over 1,000 industry leaders to discuss advancements in drug delivery systems. The event features over 150 sessio...
Oryn Therapeutics is progressing its next-generation Orynotide™ macrocyclic peptide platform aimed at treating inflammatory and autoimmune diseases through immune reprogramming rather than suppression. The company appointed Guy Rosenthal as CEO and e...
Myriad Genetics has broadened the availability of its Precise MRD test to include breast, colorectal, and renal cancers, impacting over 6 million U.S. patients. The test uses whole-genome sequencing to track tumor DNA with high sensitivity, aiding tr...
